Clinical Trials Watch
About Alzheimer Europe’s Clinical Trials Watch
The purpose of the Clinical Trials Watch is to provide accessible and up-to-date information on clinical trials (i.e. studies) that are investigating drugs for Alzheimer’s disease and/or dementia. We hope that this information is useful to affected people, their families, carers and anyone with an interest in dementia research. The Clinical Trials Watch is not an exhaustive resource of information. It contains information about clinical trials that are:
- Currently recruiting participants
- Conducted in at least two European countries
- In phase III (in these trials the drug / treatment is tested in large groups of people, involving from several hundred to several thousand participants. These trials are conducted to provide stronger evidence of the effectiveness and safety of the new drug / treatment.
Please note that you should not interpret the information provided as a recommendation to use the medicine or to participate in the study.
In the Clinical Trials Watch, you can find information by country, by condition and by study:
- By country: in this section you can see the countries in which each study is currently recruiting or is planning to recruit participants. This information is reviewed every 3 months.
- By condition: in this section you can see the condition that each study is looking at: at risk, prodromal, mild, moderate, severe dementia, agitation.
- By study: please note that a dementia-friendly version of each study is available as a pdf. This document has been reviewed by a member of the European Working Group of People with Dementia.
Who is involved in this work?
Alzheimer Europe and its European Working Group of People with Dementia have developed tables containing basic information about each trial included in the Clinical Trials Watch. The contents are based on the information available on public registries, such as the US and EU Clinical Trials Registries. You can find more information about these registries in the following links:
The pharmaceutical companies running the trials have provided feedback on the contents of the tables.
What do the tables contain?
The tables provide information on phase III clinical trials for Alzheimer’s disease and/or dementia. All the clinical trials included are currently recruiting participants. However, it is important to bear in mind that recruitment may not happen in all countries at the same time. Each table contain the following sections:
- Study Information
- Information about the drug that will be tested in the study
- Information about participating in the trial
- Who can participate in this study?
- Where and when will the study be conducted?
- Information for your doctor
What is a clinical trial?
Please click on the links below for further information on clinical trials:
For general information on clinical trials:
For information about Alzheimer Europe’s opinion on the “Participation of people with dementia in clinical trials”:
What should you do if you are interested?
People participate in clinical trials for many different reasons. Regardless of what motivates you to take part in research, it is important that you take your time to think about it, make sure that you understand what your participation will involve and if you like to, discuss this decision with your family or friends. Many trials will require that a person of your family or a close friend attends all the visits with you and if necessary, supports you in taking the medication as prescribed.
If you are considering participating in a clinical trial, it is a good idea to discuss it with your doctor first. It might be helpful to take along a family member or friend to the visit with your doctor for help and support.
Your doctor can help you to better understand the benefits and risks of participating in a clinical trial and can help you to think whether / which trial may be appropriate for you.
In some cases, you may be able to contact the pharmaceutical company running the clinical trial directly, but it is always a good idea to discuss it with your doctor first.
How can I get more information?
The tables provide an overview of the clinical trials. However, there may be information that could be relevant to you and that has not been fully addressed in the tables. For example, you may like to know more about the number of visits, the exact procedures that you will need to undergo or about the potential side effects of taking the drug that will be tested. Your doctor can help you to find out more about these details.
If you are interested in taking part in a trial, you may be invited to a screening visit with the study team. This visit will help the study team to know if you would be able to participate. During the visit you will also receive further information about the trial and your possible participation.
Below you can find a number of questions that other potential research participants have asked and might assist you in preparing for your appointment with your doctor or the study team:
- Which tests or procedures will I need to have to confirm if I can take part in the study?
- Will I be able to continue taking the medication I am currently taking?
- How is this drug different from the medication I am currently taking?
- What are the possible side effects of the medication?
- Where will I have to go for study visits? Can the doctors come to my house or will I need to go to the clinic?
- How many visits will I need to make?
- If I have to travel will my travelling expenses be paid?
- What will happen during the visits?
- What will happen if my condition gets worse?
- Will a member of my family, a friend or a carer need to be involved in any way in the study? If so, how?
- If, whilst I am in the study, I have questions, concerns or problems, is there someone in the study that I can contact easily and discuss my questions with?
- Will I be informed about the results of the study when it ends? Will this information be provided in a dementia-friendly way?
- If the drug works for me, will I be able to continue taking the drug once the study has ended?
- If the drug eventually gets onto the market, will I be informed?
Last Updated: Tuesday 19 July 2016